Next Article in Journal
A Case of Acquired Aplastic Anemia after Severe Hepatitis- Probably Induced by the Pfizer/BioNTech Vaccine: A Case Report and Review of Literature
Next Article in Special Issue
The Potential Risk Compensation after Receiving HPV Vaccination among Men Who Have Sex with Men in Southwest China: A HAPA-Based Analysis
Previous Article in Journal
The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study
Previous Article in Special Issue
Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 7
10.3390/vaccines11071227
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Vaccines 2022, 10(9), 1543.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Goodman et al. Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review. Vaccines 2022, 10, 1543

by
Elizabeth Goodman
1,*,
Miriam Reuschenbach
2,
Allysen Kaminski
3,† and
Sarah Ronnebaum
3,‡
1
Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ 07065, USA
2
Global Medical and Scientific Affairs, MSD Sharp and Dohme GmbH, 81673 Munich, Germany
3
OPEN Health, Bethesda, MD 20814, USA
*
Author to whom correspondence should be addressed.
†
Present affiliation: Milken Institute School of Public Health the George Washington University, Washington, DC 20052, USA.
‡
Present affiliation: Evidera, Inc., Bethesda, MD 20814, USA.
Vaccines 2023, 11(7), 1227; https://doi.org/10.3390/vaccines11071227
Submission received: 16 June 2023 / Accepted: 27 June 2023 / Published: 11 July 2023
(This article belongs to the Collection HPV-Vaccines)
Browse Figure
Versions Notes
The authors wish to make the following corrections to this paper [1]. In the original article, there was a mistake in Figure 2 as published. A few of the references were missed from the legend for Figure 2B,C. The corrected Figure 2 appears below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Goodman, E.; Reuschenbach, M.; Kaminski, A.; Ronnebaum, S. Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review. Vaccines 2022, 10, 1543. [Google Scholar] [CrossRef] [PubMed]
Vaccines 11 01227 g001 550
Figure 2. 4vHPV vaccine effectiveness in patients with recurrent respiratory papillomatosis. Panel (A) shows the tumor response within an individual patient defined as: CR, complete response; PR, partial response; and RD, recurrent disease. Three studies defined PR as a >50% increase in the interval between surgical procedures [32,49,50]; one study as a >50% increase in the interval between surgical procedures or persistent papillomas that were not growing and did not require surgical interventions for >12 months [34]; one study as any increase in the time to recurrence [41]; and one study as >12 months with no appreciable growth of papillomas [51]. Three studies defined the ‘PR or RD’ category as any recurrence [37–39]. No definitions were provided in the remaining two studies [17,26]. These are descriptive, within person responses, so vaccine effectiveness is not calculated. Panel (B) shows the increase in the mean intersurgical interval. The symbol * indicates statistical significance at p < 0.05. Panel (C) shows the decrease in the mean number of surgeries per month. The symbol * indicates statistical significance at p < 0.05. For all panels, data from the Rosenberg 2019 Danish cohort were collected by the study authors while data from the Romanian cohort were new, never reported data from a prior published study [52].
Figure 2. 4vHPV vaccine effectiveness in patients with recurrent respiratory papillomatosis. Panel (A) shows the tumor response within an individual patient defined as: CR, complete response; PR, partial response; and RD, recurrent disease. Three studies defined PR as a >50% increase in the interval between surgical procedures [32,49,50]; one study as a >50% increase in the interval between surgical procedures or persistent papillomas that were not growing and did not require surgical interventions for >12 months [34]; one study as any increase in the time to recurrence [41]; and one study as >12 months with no appreciable growth of papillomas [51]. Three studies defined the ‘PR or RD’ category as any recurrence [37–39]. No definitions were provided in the remaining two studies [17,26]. These are descriptive, within person responses, so vaccine effectiveness is not calculated. Panel (B) shows the increase in the mean intersurgical interval. The symbol * indicates statistical significance at p < 0.05. Panel (C) shows the decrease in the mean number of surgeries per month. The symbol * indicates statistical significance at p < 0.05. For all panels, data from the Rosenberg 2019 Danish cohort were collected by the study authors while data from the Romanian cohort were new, never reported data from a prior published study [52].
Vaccines 11 01227 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Goodman, E.; Reuschenbach, M.; Kaminski, A.; Ronnebaum, S. Correction: Goodman et al. Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review. Vaccines 2022, 10, 1543. Vaccines 2023, 11, 1227. https://doi.org/10.3390/vaccines11071227

AMA Style

Goodman E, Reuschenbach M, Kaminski A, Ronnebaum S. Correction: Goodman et al. Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review. Vaccines 2022, 10, 1543. Vaccines. 2023; 11(7):1227. https://doi.org/10.3390/vaccines11071227

Chicago/Turabian Style

Goodman, Elizabeth, Miriam Reuschenbach, Allysen Kaminski, and Sarah Ronnebaum. 2023. "Correction: Goodman et al. Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review. Vaccines 2022, 10, 1543" Vaccines 11, no. 7: 1227. https://doi.org/10.3390/vaccines11071227

APA Style

Goodman, E., Reuschenbach, M., Kaminski, A., & Ronnebaum, S. (2023). Correction: Goodman et al. Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review. Vaccines 2022, 10, 1543. Vaccines, 11(7), 1227. https://doi.org/10.3390/vaccines11071227

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop